Hennion & Walsh Asset Management Inc. Has $1.41 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
bovnews2d
What’s Fueling Intellia Therapeutics Inc (NTLA) Stock’s -53.57% Loss Below Its 200-Day SMA?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
AdvisorNet Financial Inc Buys 4,950 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...
Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating
J.P. Morgan analyst Brian Cheng has maintained their bullish stance on NTLA stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...
Intellia Therapeutics’ Strategic Reorganization and Promising Clinical Progress Justify Buy Rating
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price ...
GlobalData on MSN6d
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Nasdaq6d
13 Analysts Have This To Say About Intellia Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...
JD Supra3d
The Not-So-Safe Harbor for Research Tools: Lessons From the District of Delaware
In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...